UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Experimental cell research, ISSN 0014-4827, 2011, Volume 317, Issue 19, pp. 2765 - 2771
Oncogenic dependency | Anti-EGFR inhibitors | Personalized cancer therapy | EGFR signaling | Molecular subgroups | Colorectal cancer | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Neoplasms - metabolism | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Proto-Oncogene Proteins - genetics | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Mutation - physiology | Drug Resistance, Neoplasm - genetics | Receptor, Epidermal Growth Factor - metabolism | Animals | Neoplasms - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Molecular Targeted Therapy - methods | Care and treatment | Cancer | Cellular biology | Cancer therapies | Tumors | Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 12/2019, Volume 25, Issue 23, pp. 7089 - 7097
Journal Article
Expert opinion on therapeutic targets, ISSN 1472-8222, 01/2012, Volume 16, Issue 1, pp. 15 - 31
EGFR mutations | signaling | anti-EGFR therapy | cancer | EGFR inhibitors | therapeutic targets | EGFR | Signaling | Anti-EGFR therapy | Cancer | Therapeutic targets | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Neoplasms - metabolism | Receptor, Epidermal Growth Factor - metabolism | Animals | Signal Transduction - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Molecular oncology, ISSN 1574-7891, 02/2017, Volume 11, Issue 2, pp. 208 - 219
plasma | CRC | anti‐EGFR therapy | ctDNA | RAS mutations | anti-EGFR therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | ErbB Receptors - antagonists & inhibitors | DNA, Neoplasm - blood | Colorectal Neoplasms - blood | Colorectal Neoplasms - drug therapy | Colorectal Neoplasms - genetics | Humans | Female | Male | Aged | DNA, Neoplasm - genetics | Mutation | Genes, ras | Plasma | Epidermal growth factor receptors | Colorectal carcinoma | Colorectal cancer | Metastasis | Paraffin | Patients | Blood | Metastases | Ethics | Histopathology | Epidermal growth factor | Agreements | Clinical medicine | Deoxyribonucleic acid--DNA | DNA sequencing | Tumors | Index Medicus
Journal Article
ESMO open, ISSN 2059-7029, 07/2019, Volume 4, Issue 3, pp. e000530 - e000530
Journal Article
Molecular oncology, ISSN 1574-7891, 09/2014, Volume 8, Issue 6, pp. 1084 - 1094
Acquired resistance | RAS | Panitumumab | Colorectal cancer | Cetuximab | Anti-EGFR therapy | MET | Life Sciences & Biomedicine | Oncology | Science & Technology | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Colon - pathology | Rectum - pathology | Humans | Rectum - metabolism | Colon - drug effects | ras Proteins - metabolism | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Colon - metabolism | Animals | MAP Kinase Signaling System - drug effects | Rectum - drug effects | Signal Transduction - drug effects | Colorectal Neoplasms - drug therapy | Antineoplastic Agents - pharmacology | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins c-akt - metabolism | Colorectal Neoplasms - metabolism | Tyrosine | Health aspects | Phosphotransferases | Analysis | Genes | Immunoglobulins | Epidermal growth factor receptors | Tumor cells | Colorectal carcinoma | Extracellular signal-regulated kinase | Raf protein | AKT protein | Metastasis | Kinases | Cancer therapies | Metastases | Signal transduction | Epidermal growth factor | Xenografts | Monoclonal antibodies | Biomarkers | Mutation | Vascular endothelial growth factor | Index Medicus | Reviews | Review
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2013, Volume 18, Issue 7, pp. 850 - 864
Head and neck squamous cell carcinoma | Anti‐EGFR therapy | Intrinsic and acquired resistance | Cetuximab | Anti-EGFR therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptor, Epidermal Growth Factor - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Carcinogenesis - genetics | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Molecular Targeted Therapy | Head and Neck Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Carcinoma, Squamous Cell - drug therapy | Receptor, Epidermal Growth Factor - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Head and Neck Neoplasms - genetics | Neoplasm Recurrence, Local - genetics | Index Medicus | Head and Neck Cancers
Journal Article